Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Maya Jerath

Allergy & Immunology Saint Louis, MO Medical Doctor

NPI 1467661801 CMS profile 1230446

10 Barnes West Dr, Div Im Allergy And Immunology, Ste 200, Saint Louis, MO 63141

Open in the dashboard

General payments

$9,390

31 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$119,954 paid to institutions, not to them · program year 2025

Through program year 2025, Maya Jerath of Saint Louis, MO is reported in the CMS Open Payments database as having received $9,390 across 31 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $119,954 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 79th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $536 8
2024 General $8,383 19
2023 General $46 2
2020 General $413 1
2019 General $12 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maya Jerath
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Maya Jerath were reported at $536. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.

Show as a table
Year Maya Jerath Allergy & Immunology median Middle half National median
2019 $12 $378 $115–$1,178 $163
2020 $413 $303 $75–$1,581 $114
2021 $0 $407 $122–$1,475 $132
2022 $0 $357 $120–$1,340 $149
2023 $46 $445 $124–$1,536 $160
2024 $8,383 $541 $129–$1,763 $164
2025 $536 $682 $143–$2,317 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $7,610 13 payments
  2. AstraZeneca Pharmaceuticals LP $928 6 payments
  3. Becton, Dickinson and Company $413 1 payment
  4. CSL Behring $186 3 payments
  5. Regeneron Healthcare Solutions, Inc. $95 1 payment
  6. Genzyme Corporation $69 2 payments
  7. Pfizer Inc. $53 3 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $25 1 payment
  9. OptiNose US, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $6,438 2 payments
  2. Food and Beverage $1,602 24 payments
  3. Travel and Lodging $1,255 4 payments
  4. Education $95 1 payment
Products named General payments · program years 2019–2025
  1. TEZSPIRE $928 6 payments
  2. Hizentra $141 2 payments
  3. DUPIXENT Immunology $130 4 payments
  4. Rhapsido $117 1 payment
  5. DUPIXENT Inflammation And Immunology $95 1 payment
  6. PANZYGA $53 3 payments
  7. Haegarda $45 1 payment
  8. OCTAGAM IMMUNE GLOBULIN (HUMAN) $32 2 payments
  9. TAKHZYRO $25 1 payment
  10. CUTAQUIG $21 1 payment
  11. Other $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

484

Median for Allergy/ Immunology: 449

Drug cost

$170,050

Median for Allergy/ Immunology: $169,700

Branded share of claims

27.7%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 24 $89,615
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 17 $46,932
Cromolyn Sodium Generic 37 $13,353
Dulera Mometasone/Formoterol Brand 19 $6,290
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 26 $4,503
Epinephrine Generic 24 $3,134
Azelastine Hcl Generic 74 $2,119
Hydroxychloroquine Sulfate Generic 55 $1,061
Albuterol Sulfate Hfa Albuterol Sulfate Brand 37 $836
Ipratropium Bromide Generic 32 $817

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$796,207

Of which drugs: $763,391

Medicare patients

287

Average age 71

Services billed

40,153

211 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 60%
Osteoporosis 35%
Ischemic heart disease 26%
Depression 25%
Chronic kidney disease 24%
Diabetes 21%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 15 13,200 $230,322
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg J1561 Office 18 3,355 $129,047
Injection, denosumab, 1 mg J0897 Office 32 1,980 $37,977

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $928
$928 — —
Hizentra
  • CSL Behring $141
$141 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $95
  • GENZYME CORPORATION $31
$125 24 —
Haegarda
  • CSL Behring $45
$45 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

31 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record